Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.

doi:10.1200/JCO.2011.40.1174

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Mar 2013

Welsh James W, Komaki Ritsuko, Amini Arya, Munsell Mark F, Unger Wyatt, Allen Pamela K, Chang Joe Y, Wefel Jeffrey S, McGovern Susan L, Garland Linda L, Chen Su S, Holt Jamie, Liao Zhongxing, Brown Paul, Sulman Erik, Heymach John V, Kim Edward S, Stea Baldassarre

Abstract excerpt

PURPOSE: Brain metastasis (BM) is a leading cause of death from non-small-cell lung cancer (NSCLC). Reasoning that activation of the epidermal growth factor receptor (EGFR) contributes to radiation resistance, we undertook a phase II trial of the EGFR inhibitor erlotinib with whole-brain radiation therapy (WBRT) in an attempt to extend survival time for patients with BM from NSCLC. Additional end points were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Chemoradiotherapy

Share to Drug Administration Schedule

Share to Drug Eruptions

Share to Erlotinib Hydrochloride

Share to Kaplan-Meier Estimate

Share to Quinazolines

Source

Open in PubMed Open full text

Identifiers

PMID: 23341526
DOI: 10.1200/JCO.2011.40.1174
PMCID: PMC3577951

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.PMID 23341526Read ↗

Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma.Semantic proximity Read ↗

Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases.Semantic proximity Read ↗

Erlotinib for the treatment of brain metastases in non-small cell lung cancer.Semantic proximity Read ↗

Role of Epidermal Growth Factor Receptor (EGFR) Inhibitors and Radiation in the Management of Brain Metastases from EGFR Mutant Lung Cancers.Semantic proximity Read ↗

Phase II study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma.Semantic proximity Read ↗

Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery.Semantic proximity Read ↗

EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer.Semantic proximity Read ↗

Radiotherapy of non-small-cell lung cancer in the era of EGFR gene mutations and EGF receptor tyrosine kinase inhibitors.Semantic proximity Read ↗

EGF receptor tyrosine kinase inhibitors in the treatment of brain metastases from non-small-cell lung cancer.Semantic proximity Read ↗

Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer.Semantic proximity Read ↗

A Neuro-oncologist's Perspective on Management of Brain Metastases in Patients with EGFR Mutant Non-small Cell Lung Cancer.Semantic proximity Read ↗

Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.